Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
0.00 (4.65%)
Updated Jun 7, 2024 03:40 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 61 - 80 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; ATRC-101 Pushes Forward; BD Continues to Percolate
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Additional Monotherapy and PD-1 Combination Data in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Gates Foundation Leverages IRC Platform for Malaria; ATRC-101 Case Continues to Build
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Gates Institute Backs Atreca Malaria Prevention
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Gates MRI Agreement for Malaria Prevention Antibody
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Encouraging Signs in Initial Readout
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Targeting Stressed Tumor Cells. Additional Data in 2022.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; ATRC-101 Bursts Onto the Scene; Next Data Readout Expected in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Modest Efficacy for ATRC-101; Combination Potential Ahead; PT to $12
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing First Look at ATRC-101 Data in Very Sick Population; Much More to Come
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Forthcoming Diagnostic Important to Efficacy of Cancer Drug
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T